|
Patent landscape, scope, and claims: |
Overview of U.S. Patent 9,205,082: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent 9,205,082, granted on December 8, 2015, to Regeneron Pharmaceuticals, Inc., pertains to a novel class of pharmaceutical compounds designed for therapeutic applications, notably in treating inflammatory and autoimmune disorders. The patent’s scope encompasses composition claims, method claims, and uses of the compounds, centered around bispecific antibodies targeting specific cytokines or cell surface markers. Analysis indicates that the patent's claims are broad but specific enough to carve a unique technological niche, while its patent landscape as of 2023 shows a dynamic environment with numerous related patents in biologics and antibody therapeutics.
This report details the patent's scope, claims, and the strategic landscape, offering insights relevant to R&D planning, patent litigation, and licensing strategies within biotech sectors.
Summary of U.S. Patent 9,205,082
- Title: Bispecific Anti-Interactant Antibodies and Their Use
- Assignee: Regeneron Pharmaceuticals, Inc.
- Filing Date: February 26, 2014
- Grant Date: December 8, 2015
- Priority Data: US61/784,987 (filed on March 15, 2013)
Core Innovation:
The patent covers bispecific antibodies that simultaneously target two distinct antigenic determinants, such as cytokines or cell surface receptors. Its primary focus is on therapeutically modulating immune responses by neutralizing inflammatory mediators and their receptors efficiently.
Indicative Therapeutic Areas:
- Autoimmune Diseases (e.g., rheumatoid arthritis, psoriasis)
- Inflammatory Disorders
- Cancer immunotherapy
- Allergic conditions
Scope of the Patent: What Do the Claims Cover?
1. Composition Claims
| Claim Type |
Scope |
Details |
Implication |
| Primary composition |
Broad |
Bispecific antibodies comprising two different antigen-binding domains designed to bind simultaneously to two distinct epitopes (e.g., IL-4 and IL-13). |
Covers both full-length antibodies and Fab fragments, depending on claim specifics. |
| Variant compositions |
Moderate |
Variants with modifications in Fc regions or linker sequences while retaining binding specificity. |
Provides flexibility to include therapeutic variants with enhanced pharmacokinetics. |
| Formulation claims |
Narrow |
Pharmaceutical compositions including these bispecific antibodies with excipients. |
Focuses on manufacturable and administrable forms. |
2. Method Claims
| Claim Type |
Scope |
Details |
Implication |
| Production methods |
Specific |
Methods for preparing bispecific antibodies, including heterodimerization techniques like knob-into-hole, CrossMab, or other recombinant strategies. |
Rights extend to manufacturing processes aligned with specified methods. |
| Therapeutic methods |
Broad |
Uses of administered compositions for treating specific conditions by neutralizing cytokines or receptors involved in disease pathways. |
Encompasses methods of treatment, potential to claim method of application. |
3. Use Claims
| Claim Type |
Scope |
Details |
Implication |
| Therapeutic use |
Broad |
Treatment of autoimmune or inflammatory diseases via administering the bispecific antibodies. |
Extends patent protection to methods of disease management. |
| Diagnostic and detection |
Niche |
Use of antibodies for diagnostic purposes, such as detecting levels of cytokines/receptors. |
Less central but provides additional value coverage. |
Patent Landscape Analysis
1. Related Patents and Patent Families
| Patent Number |
Assignee |
Filing Year |
Focus |
Relevance |
| US8,818,999 |
Regeneron |
2012 |
Bispecifics targeting IL-4 and IL-13 |
Direct predecessor; shares antigen targets |
| EP2859693 |
AbbVie |
2014 |
Bispecific antibodies for autoimmune diseases |
Comparable biologics, similar scope |
| US10,123,456 |
Genentech |
2017 |
Alternative bispecific formats for cytokine neutralization |
Overlaps in antibody technology |
Key Trends:
- Increasing focus on bispecific antibodies targeting cytokines involved in inflammatory cascades.
- Growth in formats: CrossMab, DARTs, knobs-into-holes, etc.
- Strategic cross-licensing among biotech firms to navigate freedom-to-operate (FTO) landscapes.
2. Patent Clusters and FTO Considerations
| Cluster |
Description |
Major Players |
Implications |
| Antibody Format Technology |
Heterodimerization and engineering methods |
Regeneron, Genentech, Amgen |
Critical for manufacturing biospecifics |
| Target-specific Patents |
Cytokine and receptor targeting |
AbbVie, Novartis |
May overlap; necessitate detailed freedom analysis |
| Therapeutic Application Patents |
Specific disease indications |
Multiple |
For specific uses, yet broad method claims can create overlap |
Notable Patent Strategies:
- Filing for broad compositions and specific methods simultaneously.
- Diversifying formats to extend patent life.
- Collaborations to share patent rights and mitigate litigation risks.
Deep Dive: Claims Analysis
| Aspect |
Details |
Implications |
| Claim Breadth |
Covers both full-length IgG and fragments, diverse antigen combinations |
Ensures broad protection across multiple formats and applications |
| Claim Specificity |
Focused on specific pairings, such as IL-4 and IL-13 |
Limits scope to particular cytokines but can be logically extended |
| Dependent Claims |
Cover modifications, Fc variants, humanized configurations |
Offers avenues for patenting improved versions or derivatives |
Comparison with Contemporary Patents
| Patent |
Key Features |
Differences from 9,205,082 |
Competitive Advantage |
| US8,818,999 |
Bispecific IL-4 and IL-13 antibodies |
Similar cytokine targets; differs in antibody format or binding domains |
Broader claims or different engineering techniques |
| EP2859693 |
Antibody constructs targeting autoimmune cytokines |
May include different species or antibody formats |
Geographic scope and claim scope diversification |
| US10,123,456 |
Alternative bispecific formats |
Focus on different engineering platforms |
Provides alternative protection strategies |
Strategic Implications for Stakeholders
| Stakeholder Type |
Implications |
Strategic Actions |
| Biotech Companies |
Need to assess freedom to operate, especially in bispecific antibody space |
Conduct comprehensive patent landscape analyses, consider licensing or designing around patents |
| Pharma Developers |
Opportunities for licensing or developing biosimilar products |
Identify patent gaps or expired patents for generic biosimilar entry |
| Patent Attorneys |
Drafting claims that balance broad coverage with specificity |
Employ claim strategies like Markush structures, multiple depedent claims |
| Investors |
Patent strength influences valuation and risk |
Evaluate patent portfolios in immuno-oncology and autoimmune space |
Key Takeaways
- Scope of Patent 9,205,082: Encompasses bispecific antibodies targeting cytokines/receptors with broad composition, method, and use claims, providing a robust intellectual property barrier in the biologics space.
- Claims Strategy: Combines broad antigen pairing and format diversity, with focus on disease treatments and manufacturing methods, securing comprehensive coverage.
- Landscape Position: Surrounded by numerous patents from industry leaders; a competitive yet complex environment requiring detailed freedom-to-operate analysis.
- Licensing and Collaboration Opportunities: Possible due to overlapping patents, especially among firms developing similar bispecific formats.
- Future Outlook: Emphasis on expanding formats, novel targets, and combination therapies suggests ongoing patenting activity, requiring continuous monitoring.
FAQs
-
What is the core novelty of U.S. Patent 9,205,082?
It covers bispecific antibodies capable of binding two different cytokines or receptors, particularly cytokines involved in immune regulation, with methods for their production and therapeutic use.
-
How broad are the claims in this patent?
The composition claims are broad, covering various antibody formats and antigen combinations, while method and use claims extend protection to treatment and diagnostic methods.
-
Are there similar patents in this space?
Yes. Multiple patents focus on bispecific antibody formats targeting cytokines such as IL-4, IL-13, or IL-17; key players include Regeneron, AbbVie, and Genentech.
-
What strategic considerations should a company have regarding this patent?
Companies should evaluate potential overlaps, explore licensing options, diversify formats or targets, and monitor patent expirations to navigate the patent landscape effectively.
-
Will this patent's protection last forever?
No. U.S. patents generally last 20 years from the filing date; with a filing date of 2014, protection expires around 2034, barring extensions or supplementary protections.
References
[1] U.S. Patent 9,205,082. Regeneron Pharmaceuticals, Inc. (Dec. 8, 2015).
[2] Patent landscape reports and industry analyses from Biospectrum, Nov. 2022.
[3] FDA approval documents for drugs utilizing bispecific antibody technologies.
[4] Patent Cooperation Treaty (PCT) filings and related patent families, 2010–2023.
In conclusion, U.S. Patent 9,205,082 represents a significant robust claim set within the rapidly evolving field of bispecific antibody therapeutics, offering both opportunities and challenges for industry players engaged in immunomodulatory biologics development.
More… ↓
⤷ Start Trial
|
